Commentary: Are we at a CROSSroads in neoadjuvant therapy for esophageal cancer?

[摘要] It has been 12 years since publication of the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study trial set the standard of care for neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced esophageal cancer.1 More recently, the CALGB 80803 trial demonstrated higher rates of pathologic complete response with a fluorouracil-based, positron-emission tomography--directed neoadjuvant strategy.2 Long-term outcomes from this trial are pending. Recurrence, particularly distant recurrence, continues to limit survival in locally advanced esophageal cancer.

[学科分类] 心脏病和心血管学